Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINNOVATE: Lurbinectedin, Ipilimumab, and Nivolumab in Advanced Soft Tissue Sarcoma
NCT05876715Phase 2Recruiting
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in soft tissue sarcoma (STS). Started Jun 2023; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05876715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876715.